GRN and colorectal carcinoma: In conclusion, this study demonstrates the contribution of progranulin in sustaining STAT3 oncogenic activity in CRC and suggests that progranulin inhibitors, either alone or in combination with conventional cytotoxic agents, can be promising approaches for therapeutic interventions in selected CRC subgroups marked by high levels of active STAT3.